Provider Briefing: Clindamycin Supply Disruptions in 2026

Clindamycin remains one of the most frequently prescribed antibiotics across specialties — from primary care and dentistry to surgery and infectious disease. Its broad coverage against gram-positive aerobes, anaerobes, and certain MRSA strains makes it a cornerstone of empiric therapy, particularly for patients with penicillin allergies.

However, ongoing supply disruptions — especially for injectable formulations — continue to challenge prescribers and health systems in 2026. This article provides a comprehensive overview of the current shortage landscape, prescribing considerations, alternative agents, and tools to help your patients access their medications.

Shortage Timeline

The Clindamycin Phosphate Injection shortage has been a recurring issue since 2021, with intermittent periods of limited availability across multiple manufacturers:

• 2021-2022: Initial reports of supply constraints from several injectable manufacturers. The shortage was listed on both the FDA and ASHP drug shortage databases.
• 2023-2024: Continued back orders from Sagent (150 mg/mL 60 mL vials), Pfizer (Cleocin 150 mg/mL 4 mL vials), and Baxter (premixed IV bags). Limited allocations became the norm for hospital pharmacies.
• 2025: Pfizer estimated a release date of December 2025 for certain Cleocin injectable products. Baxter maintained limited allocation of premixed bags in 0.9% sodium chloride. Some short-dated 900 mg/50 mL premixed bags became available.
• 2026 (current): The injectable shortage persists. Sagent vials remain on back order with no estimated release date. Some premixed IV bag availability has improved, though with short expiration windows. Oral and topical formulations remain largely unaffected.

Prescribing Implications

The ongoing shortage has several practical implications for prescribers:

Inpatient Settings

• Hospital pharmacy departments may implement formulary restrictions or automatic therapeutic substitution protocols for IV Clindamycin
• Consider oral step-down therapy earlier when clinically appropriate — Clindamycin has excellent oral bioavailability (approximately 90%)
• For surgical prophylaxis in penicillin-allergic patients, institutional guidelines may recommend alternatives such as Vancomycin or Aztreonam + Metronidazole

Outpatient Settings

• Oral Clindamycin capsules (150 mg, 300 mg) are generally available, though local stock may vary
• Increased prescribing of oral forms due to the injectable shortage may cause intermittent retail pharmacy stock-outs
• Patients may need to check multiple pharmacies — direct them to Medfinder for Providers to verify stock availability

Antibiotic Stewardship

The shortage provides an opportunity to reinforce stewardship principles:

• Reserve Clindamycin for situations where it offers clear clinical advantage over available alternatives
• Document the clinical rationale when prescribing Clindamycin during active shortages
• Consider antibiogram data when selecting alternatives — local resistance patterns should guide empiric therapy decisions

Current Availability Picture

Here's a formulation-by-formulation breakdown of availability as of early 2026:

• Injectable (150 mg/mL vials): Severely constrained. Sagent 60 mL vials on back order (no estimated release). Pfizer Cleocin 4 mL vials intermittently available.
• Premixed IV bags: Limited. Baxter has allocation-restricted supply. Short-dated 900 mg/50 mL bags available through some distributors.
• Oral capsules (75 mg, 150 mg, 300 mg): Generally available from multiple generic manufacturers. Occasional local stock-outs.
• Oral solution (75 mg/5 mL): Available. Important option for pediatric patients and those who cannot swallow capsules.
• Topical (1% gel, lotion, foam, solution): Available. Multiple generics and branded products (Cleocin T, Clindagel, Evoclin).
• Vaginal (2% cream, suppositories): Available. Including newer single-dose option Xaciato.

Cost and Access Considerations

Generic oral Clindamycin remains one of the more affordable antibiotics:

• Cash price for oral capsules: $17-$50 for a typical course (30-40 capsules) without insurance; as low as $17-$25 with discount programs
• Insurance coverage: Tier 1 or Tier 2 on most formularies (Medicare Part D, Medicaid, commercial plans); no prior authorization typically required
• Patient assistance: NeedyMeds discount card, GoodRx, SingleCare, and RxSaver all offer significant savings on generic Clindamycin

For patients struggling with cost, direct them to: How to Save Money on Clindamycin in 2026.

Tools and Resources for Providers

Several tools can help you and your patients navigate the shortage:

• Medfinder for Providers — Real-time pharmacy stock searches to help patients locate Clindamycin in their area. Integrates into clinical workflows.
• ASHP Drug Shortage Resource Center — Updated shortage details, manufacturer timelines, and therapeutic alternatives for Clindamycin Phosphate Injection
• FDA Drug Shortage Database — Official shortage status and manufacturer communications
• Institutional P&T committees — Work with your pharmacy and therapeutics committee to develop shortage management protocols and automatic substitution guidelines

Therapeutic Alternatives

When Clindamycin is unavailable or clinically inappropriate, consider these alternatives based on indication:

• Skin/soft tissue infections (including MRSA): Doxycycline, Trimethoprim/Sulfamethoxazole (Bactrim), Linezolid (for severe cases)
• Dental/oral infections: Amoxicillin/Clavulanate (if no penicillin allergy), Metronidazole, Azithromycin
• Intra-abdominal/pelvic infections: Metronidazole (often in combination with a cephalosporin or fluoroquinolone)
• Respiratory infections: Azithromycin, Doxycycline, respiratory fluoroquinolones
• Surgical prophylaxis (penicillin-allergic): Vancomycin, Aztreonam + Metronidazole
• Acne (topical): Benzoyl Peroxide, Adapalene, topical Erythromycin, topical Dapsone

For more detailed alternative information to share with patients: Alternatives to Clindamycin If You Can't Fill Your Prescription.

Looking Ahead

The structural issues driving injectable antibiotic shortages — limited manufacturer diversity, thin profit margins on generics, aging production facilities — are not unique to Clindamycin. Industry-wide efforts to strengthen the generic injectable supply chain are ongoing, but resolution will take time.

In the meantime, the most effective approach is a combination of proactive shortage management, evidence-based therapeutic substitution, and leveraging real-time tools to help patients access available supply.

Final Thoughts

The Clindamycin shortage continues to be a manageable challenge in 2026, particularly since oral and topical formulations remain largely available. The key for providers is staying informed about which formulations are affected, having alternative protocols in place, and directing patients to resources like Medfinder to find their medications.

For the provider-focused guide on helping patients directly, see: How to Help Your Patients Find Clindamycin in Stock: A Provider's Guide.